Navigation Links
BioMarin Announces Buy Back of Naglazyme Royalties From Adelaide Health Authority
Date:11/30/2011

NOVATO, Calif., Nov. 30, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has completed the buy back of certain intellectual property from SA Pathology, a unit of the Central Adelaide Local Health Network located in Adelaide, Australia for an upfront payment of $81 million.  The intellectual property includes patents related to the purified form of Naglazyme and the method of using the enzyme in the treatment of MPS VI, which expire between 2022 and 2023.  Prior to this transaction, BioMarin licensed this intellectual property from SA Pathology and paid a five percent royalty on net sales of Naglazyme. 

"We are pleased to complete this transaction as we are confident in the future sales potential of Naglazyme.  We continue to expand the product into new geographies and expect steady growth for years to come.  We do not see any competition on the horizon due to the extremely small patient population, the complexity and expense of manufacturing the product and the intellectual property covered by the patents," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.  "The transaction will allow BioMarin to generate approximately $10 to $15 million in cash per year with no incremental operating costs.  This deal makes sense for BioMarin because we see continued growth in the global Naglazyme business."

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which B
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
2. BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility
3. BioMarin to Host a Research and Development Day on December 8th
4. BioMarin Announces Third Quarter 2011 Financial Results
5. BioMarin to Present at the UBS Global Life Sciences Conference
6. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
7. BioMarin to Present at the Baird Health Care Conference
8. BioMarin to Present at the Wedbush Life Sciences Conference
9. BioMarin Announces Second Quarter 2011 Financial Results
10. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
11. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... Brazil and ... and commonly prescribe long-acting beta-agonist (LABA)- and long-acting ... so within current severe cost/coverage constraints. Therefore, new ... expected to launch in these countries—which will considerably ...
(Date:8/21/2014)... MISSION, Kan. , Aug. 21, 2014 /PRNewswire-iReach/ ... Information Trust Alliance (HITRUST) under its Common Security ... ScriptPro,s Enterprise Security and Privacy Manager, "We appreciate ... the level of commitment that this certification signifies. ... compliant." ABOUT THE CSF CERTIFICATION PROCESS: ...
(Date:8/21/2014)... , August 21, 2014 ... BreedIT Ltd., the exclusive worldwide license holder and ... plant breeders and researchers, today is pleased to ... venture with Seach Ltd, a leading Israeli medical ... research and develop new breeds of medical Cannabis ...
Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3ScriptPro Achieves HITRUST Certification 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4
... 26 Paratek Pharmaceuticals, Inc. today,announced positive Phase ... a first-in-class aminomethylcycline (AMC). The Phase 2 study ... forms of PTK 0796 to,Zyvox(R) in the treatment ... (cSSSIs). Paratek,s trial met its primary safety and,tolerability ...
... affirmed the clinical benefits of,ACTEMRA -, NUTLEY, ... III studies,showed that patients who suffer from the ... significant improvements in signs and,symptoms when treated with ... with methotrexate alone. The final results of,both studies ...
Cached Medicine Technology:Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 2ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 3ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 5ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 6
(Date:8/22/2014)... August 22, 2014 Until now, those with ... crutches or walkers to keep mobile. Thanks to an inventor ... much more effective. , He developed a prototype for the ... injured leg or foot but provide comfort and reduce pain ... different heights, it is also convenient and easy to install ...
(Date:8/22/2014)... a wide range of epigenetic changesalterations in DNA across the ... with Crohn,s disease (CD), reports Inflammatory Bowel Diseases ... Foundation of America (CCFA). The journal is published ... Wolters Kluwer Health . , The study ... of the genome in children with CD, according to Professor ...
(Date:8/22/2014)... lymphoma will be able to better understand their risks ... premature menopause with different treatments. , The findings, set ... Institute , are based on the experience of more ... for the cancer over a period of more than ... with Hodgkin lymphoma who receive certain types of chemotherapy ...
(Date:8/22/2014)... Watertown, MA (PRWEB) August 22, 2014 ... Health (IFNH) at Rutgers, the State University of ... , an innovative children’s media organization, to educate young ... that will build on the strengths of both organizations. ... ChopChop Magazine, a health communications fellowship program, and video ...
(Date:8/22/2014)... Ticket Down is a reliable source for cheap ... Rentschler Field. There has never been a better time to be ... After the strong showing at the 2014 World Cup in Brazil, ... featured in large stadiums around the country. Since the World Cup ... some of the best club teams in the sport played on ...
Breaking Medicine News(10 mins):Health News:Assistive Device for Walking Invented by InventHelp Client (VBL-501) 2Health News:Study shows epigenetic changes in children with Crohn's disease 2Health News:Scientists map risk of premature menopause after cancer treatment 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 3Health News:USA vs. Ecuador Tickets: Ticket Down Slashes USA (USMT) vs. Ecuador Tickets at Rentschler Field in East Hartford on Oct. 10th 2Health News:USA vs. Ecuador Tickets: Ticket Down Slashes USA (USMT) vs. Ecuador Tickets at Rentschler Field in East Hartford on Oct. 10th 3
... review investigating the effectiveness of a publicly funded graphic ... been associated with many negative outcomes. The review ... Science , a peer reviewed journal of the Society ... was created in 2005 to reduce methamphetamine use in ...
... or the "Company"), a leading provider of laser vision,correction services under the LasikPlus(R) ... stockholders in response to,recent letters from those stockholders to the Board. , ... Company,s Board of Directors appears,below: , , ... December ...
... Visit Atlantic City , , ATLANTIC CITY, ... who had been wounded in the Iraq conflict and recuperating at Walter ... a visit to Harrah,s Resorts in Atlantic City. , ... women, recovering , from war injuries and wishing for the ...
... N3 Oceanic, Inc. announced the addition of Orosine to ... cardiologist Dr. Jeffrey Shapiro, MD, Assistant Professor of Internal ... Langone Medical Center, who has been giving the formula to ... Dr. Shapiro states, Orosine is the most significant natural product ...
... Precision Optics,Corporation, Inc., (OTC Bulletin Board: POCI) ... the company,s common stock. Stockholders approved,the reverse split ... 2008. The,Board of Directors has determined that the ... Precision Optics Corporation and its stockholders, providing,the benefits ...
... are not being provided in Zimbabwe. The public health system ... Staggering inflation and unemployment have resulted in shortages of food ... of cholera, which is being spread by a shortage of ... date, the outbreak has claimed over 600 lives. , ...
Cached Medicine News:Health News:Success of anti-meth ads questioned by study 2Health News:Success of anti-meth ads questioned by study 3Health News:LCA-Vision Board of Directors Responds to Recent Letters from Stockholder Group 2Health News:LCA-Vision Board of Directors Responds to Recent Letters from Stockholder Group 3Health News:LCA-Vision Board of Directors Responds to Recent Letters from Stockholder Group 4Health News:Wounded Warriors to be Holiday Guests of Harrah's Entertainment 2Health News:Res-Q Gains Rights To Market Orosine - a Breakthrough, Patented, Natural Heart Supplement That Cardiologists Are Calling the 'Ultimate Cardio Protection' Against Heart Attacks, Strokes and Heart Failure. 2Health News:Precision Optics Corporation to Effect Reverse Split and Ticker Symbol Change 2
55 DSL's new collection of optical frames has established a strong personality and developed,superficial retro concepts with contemporary styles and strong impacting colours....
... and highly sought-after, the ... collection of sunglasses and ... the very latest men's ... timeless sources of inspiration ...
... Extended Ablation laser enables the physician to provide ... results and no downtime., The new Whisper NG ... an extra long pulse width to achieve "Extended ... over 3-5 days, and occurs simultaneously with the ...
... the art software package designed to assist in ... by a lens manufacturer with years of experience ... is designed to help you run your lab ... the software dictates., ,Designed specifically for integrated retail ...
Medicine Products: